International Society for Heart and Lung Transplantation
Patients implanted with VAD via thoracotomy may have improved outcomes
Patients with end-stage HF who have had a ventricular assist device implanted by thoracotomy procedure were alive and did not have adverse events at 6 months, according to results from the HVAD LATERAL study presented at the International Society for Heart and Lung Transplantation Scientific Meeting.
ENDURANCE Supplemental: Centrifugal-flow LVAD with BP management confers benefits
Patients with advanced HF ineligible for a transplant who were implanted with a centrifugal-flow left ventricular assist device and received BP management were more likely to survive and be free of disabling stroke than those implanted with an alternative LVAD, according to the ENDURANCE Supplemental trial results presented at the International Society for Heart and Lung Transplantation Annual Meeting and Scientific Sessions.
Updated LVAD yields fewer adverse events in patients with HF
Patients who received a new-generation left ventricular assist device experienced fewer hemocompatibility-related clinical adverse events compared with those implanted with an older device, according to new findings.